Nantahala Capital Management, LLC Akebia Therapeutics, Inc. Call Options Transaction History

Nantahala Capital Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $309,056 - $647,086	-965,800 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.72 - $2.93 $24,624 - $100,206	-34,200 Reduced 3.42%	965,800 $693,000
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $2.26 Million - $3.34 Million	-1,000,000 Reduced 50.0%	1,000,000 $2.26 Million
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $6.5 Million - $12.8 Million	1,586,000 Added 383.09%	2,000,000 $9.68 Million
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $2.36 Million - $4 Million	-437,000 Reduced 51.35%	414,000 $2.29 Million
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $5.04 Million - $6.25 Million	551,000 Added 183.67%	851,000 $8.49 Million
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $2.86 Million - $4.7 Million	300,000 New	300,000 $2.86 Million

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.